Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results matching your filters

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideRecruiting
NCT07454837Phase 2, Phase 3Updated Sep 10, 2026
Sponsor: Mirum Pharmaceuticals, Inc.
Chronic Hepatitis D
Austria, Czechia, France, Germany, Italy +3 more
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruiting
NCT05675410Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
United States, Canada, Puerto Rico
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaRecruiting
NCT07504458Phase 3Updated Sep 10, 2026
Sponsor: Quetzal Therapeutics
Acute Promyelocytic Leukemia (APL) · Acute Promyelocytic Leukaemia · Acute Promyelocytic Leukemia With PML-RARA · Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
United States, France, Romania, Spain
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialRecruiting
NCT06498635Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8 · Stage IIIA Lung Cancer AJCC v8 · Stage IIIB Lung Cancer AJCC v8
United States
A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety DisorderRecruiting
NCT07767903Phase 3Updated Sep 10, 2026
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
United States
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.Recruiting
NCT07619131Phase 3Updated Sep 10, 2026
Sponsor: AstraZeneca
Hypercholesterolaemia
United States, Bulgaria, Canada, Denmark, Germany +6 more
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsRecruiting
NCT05835310Phase 3Updated Sep 10, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States, Argentina, Brazil, Canada, China +12 more
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)Recruiting
NCT07811869Phase 3Updated Sep 10, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Pruritus of Unknown Origin
United States
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruiting
NCT04269902Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Canada
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesRecruiting
NCT07670416Phase 3Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Obesity · Overweight · Type 2 Diabetes Mellitus (T2DM)
China
Pridopidine Phase 3 Study in Huntington's DiseaseRecruiting
NCT07609108Phase 3Updated Sep 10, 2026
Sponsor: Prilenia
Huntington Disease
United States, Belgium, Canada, Czechia, France +7 more
Xylitol and the Prevention of Periodontal Disease and Preterm Birth TrialRecruiting
NCT07424846Phase 2, Phase 3Updated Sep 10, 2026
Sponsor: University of Washington
Preterm Birth · Low Birthweight Neonate · Periodontitis · Gingivitis
Malawi
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruiting
NCT06943755Phase 2, Phase 3Updated Sep 10, 2026
Sponsor: Exelixis
Pancreatic Neuroendocrine Tumor (pNET) · Extra-Pancreatic Neuroendocrine Tumor (epNET)
United States, Australia, Austria, Belgium, Brazil +12 more
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataRecruiting
NCT07733765Phase 3Updated Sep 10, 2026
Sponsor: Pfizer
Alopecia Areata
United States, Canada, Japan
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Recruiting
NCT03486873Phase 3Updated Sep 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Solid Tumors · Hematologic Malignancies
United States, Argentina, Australia, Austria, Belgium +46 more
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisRecruiting
NCT06408259Phase 3Updated Sep 10, 2026
Sponsor: Bristol-Myers Squibb
Multiple Sclerosis, Relapsing-Remitting
United States, Australia, Italy, Mexico, Poland +6 more
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerRecruiting
NCT05946213Phase 3Updated Sep 10, 2026
Sponsor: NRG Oncology
Prostate Adenocarcinoma · Stage III Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8
United States, Canada, Hong Kong, Switzerland
A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRecruiting
NCT07067463Phase 3Updated Sep 10, 2026
Sponsor: Zenas BioPharma (USA), LLC
Multiple Sclerosis (MS) Primary Progressive
United States, Bulgaria, Croatia, Czechia, Estonia +11 more
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)Recruiting
NCT07775287Phase 3Updated Sep 10, 2026
Sponsor: Genmab
Colorectal Cancer
Puerto Rico
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)Recruiting
NCT07210515Phase 3Updated Sep 10, 2026
Sponsor: Ambros Therapeutics, Inc.
Complex Regional Pain Syndrome Type I
United States
Lumateperone for Late-Life DepressionRecruiting
NCT07623135Phase 3Updated Sep 10, 2026
Sponsor: Eric Lenze
Treatment Resistant Depression (TRD) · Late Life Depression (LLD) · Depression / Major Depressive Disorder
United States
Building Adaptive School-based Interventions for CariesRecruiting
NCT07265830Phase 3Updated Sep 10, 2026
Sponsor: University of Pennsylvania
Dental Caries
United States
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruiting
NCT06058377Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · HER2-Negative Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma
United States, Puerto Rico
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer PatientsRecruiting
NCT06379113Phase 2, Phase 3Updated Sep 10, 2026
Sponsor: Xiaojun Chen
Endometrial Neoplasms · Atypical Endometrial Hyperplasia · Progesterone Resistance · Obesity
China
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruiting
NCT05987241Phase 2, Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Renal Pelvis Urothelial Carcinoma · Muscle Invasive Ureter Urothelial Carcinoma · Muscle Invasive Urethral Urothelial Carcinoma
United States, Canada

Previous page Next page